Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

Emmaus Life Sciences, Inc. announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for PDAC.